Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UV1 Vaccination in NSCLC
NCT01789099Phase 2Completed
- Sponsor
- Ultimovacs ASA
- Start
- Apr 2013
- Primary completion
- Feb 2016
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of UV1 in non-small cell lung cancer (NSCLC), sponsored by Ultimovacs ASA. Started Apr 2013; status: completed.
02
Drugs
UV1
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01789099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01789099.